Recent Financings Of Private Companies, January 2013
This article was originally published in Start Up
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings of Start-Ups column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Pharmaceuticals, and Medical Devices sectors.
You may also be interested in...
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.
Device company M&A values reached $17.9bn in Q3, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
During the third quarter, device company fundraising totaled $3.3bn; while in vitro diagnostic firms and research tools players raised $3.4bn.